Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
P 2 (3)
P 3 (1)

Trial Status

Enrolling By Invitation2
Not Yet Recruiting1
Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT07517419Phase 2Enrolling By InvitationPrimary

PIPAC in Gastric Peritoneal Metastasis

NCT07304258Phase 2Not Yet RecruitingPrimary

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

NCT07304271Phase 3RecruitingPrimary

Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastasis

NCT06487715Phase 2Enrolling By InvitationPrimary

Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis

Showing all 4 trials

Research Network

Activity Timeline